Gemcitabine or Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation in Non Small Cell Lung Cancer (NSCLC)

• Status: Completed
• Trial end date: 2009-02-01
• Target enrollment: 0
• Participant gender: All

Summary

To assess the 2 year survival of patients with Stage III unresectable non-small cell lung cancer receiving consolidation gemcitabine or gemcitabine plus docetaxel following concurrent chemotherapy and radiation.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Cisplatin; Docetaxel; Etoposide; Etoposide phosphate; Gemcitabine

Criteria

Inclusion Criteria:

• histologic or cytologic proof of single primary non-small cell lung cancer

• No prior chemotherapy or radiation therapy

• no prior malignancy

Exclusion Criteria:

• pregnancy or breastfeeding

• serious concomitant systemic disorder

• unintentional weight loss greater than 10%